Ms Lisa Piccolo, PHYSICAL THERAPIST in Port Ewen, NY - Physical Therapist

Ms Lisa Piccolo, PHYSICAL THERAPIST is a Physical Therapist based in Port Ewen, New York. Ms Lisa Piccolo is licensed to practice in New York (license number 015113-1) and her current practice location is 319 Broadway, Ulster Boces Alternative Education, Port Ewen, New York. She can be reached at her office (for appointments etc.) via phone at (845) 339-8707.

NPI number for Ms Lisa Piccolo is 1194092171 and her current mailing address is 319 Broadway, Ulster Boces Alternative Education, Port Ewen, New York. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1194092171.

Contact Information

	Ms Lisa Piccolo, PHYSICAL THERAPIST
	319 Broadway, Ulster Boces Alternative Education, Port Ewen, NY 12466
	(845) 339-8707
	Not Available

Healthcare Provider's Profile

Full Name	Ms Lisa Piccolo
Gender	Female
Speciality	Physical Therapist
Location	319 Broadway, Port Ewen, New York
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1194092171
Provider Enumeration Date: 11/19/2011
Last Update Date: 07/10/2012

Medical Identifiers

Medical identifiers for Ms Lisa Piccolo such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1194092171	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
225100000X	Physical Therapist	015113-1 (New York)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Ms Lisa Piccolo is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Ms Lisa Piccolo, PHYSICAL THERAPIST 319 Broadway, Ulster Boces Alternative Education, Port Ewen, NY 12466 Ph: (845) 339-8707	Ms Lisa Piccolo, PHYSICAL THERAPIST 319 Broadway, Ulster Boces Alternative Education, Port Ewen, NY 12466 Ph: (845) 339-8707

News Archive

Schering-Plough Corporation settles with $27 million to the State of Texas

Schering-Plough Corporation has announced that it has reached an agreement with the Attorney General's Office of the State of Texas to settle issues related to reimbursement by Texas' Medicaid program of albuterol sulfate solution and inhaler products.

Accellent to refinance its existing senior secured credit facilities

Accellent Inc. announced today that it has adopted a plan to refinance (the "Refinancing") its existing senior secured credit facilities and replace them with indebtedness that has longer-dated maturities. The plan, which has been unanimously approved by the Company's Board of Directors, would strengthen the Company's capital structure by extending nearer term maturities such that the Company has no maturities until November 2013.

Pfizer subsidiary extends tender offer to acquire King to January 21, 2011

Pfizer Inc. today announced that its wholly-owned subsidiary, Parker Tennessee Corp., has extended the expiration date of its tender offer for all outstanding shares of common stock of King Pharmaceuticals, Inc. for $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes.

Watson Laboratories files ANDA for generic Aplenzin ER in treatment of major depressive disorder

Watson Pharmaceuticals, Inc., a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.- Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its 174 mg and 348 mg strength bupropion hydrobromide tablets prior to the expiration of patents owned by Biovail. Watson's 174 mg and 348 mg strength bupropion hydrobromide tablet products are generic versions of Biovail's Aplenzin™ ER, which is indicated for major depressive disorder.

Experts reveal improved survival for patients with two out of three types of advanced breast cancer

Patients with two out of the three most common types of advanced breast cancer now have an average survival time of at least five years, according to a panel of experts at the Advanced Breast Cancer Sixth International Consensus Conference (ABC 6).

Ms Lisa Piccolo, PHYSICAL THERAPIST - Physical Therapist in Port Ewen, NY